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ABSTRACT
Resistant hypertension is defined as blood pressure that remains above 140/90 mm Hg despite the concurrent use of optimal dose of 3 antihy-
pertensive agents of different classes. Ideally, 1 of these 3 agents should be a diuretic agent. The etiology of resistance hypertension is multi-
factorial. Successful treatment requires identification and reversal of lifestyle factors (obesity, dietary salt intake, alcohol intake, lack of adher-
ence to prescribed medicines, and interfering substances), and to exclude the presence of pseudoresistance. Once confounding factors have 
been ruled out, evaluation for potentially treatable secondary causes of hypertension should be considered. Most forms of secondary hyperten-
sion are related with adrenal or renal disorders such as primary hyperaldosteronism and renovascular disease. Although, obstructive sleep 
apnea syndrome is not a typical cause of secondary hypertension, it is commonly present in resistant hypertension. Diagnostic workup and 
management of resistant hypertension were discussed in different clinical presentations. (Anadolu Kardiyol Derg 2014; 14: 192-5)
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Introduction
Resistant hypertension is defined as blood pressure that 
remains above 140/90 mm Hg despite the concurrent use optimal 
doses of 3 antihypertensive agents of different classes, one 
being a diuretic. The spectrum of resistant hypertension also 
includes patients whose blood pressure can be controlled by 
four or more medications. The exact prevalence of resistant 
hypertension is unknown but the reported prevalence is 10-15% 
at reference clinics.
The accurate diagnosis and appropriate evaluation of resis-
tant hypertension require exclusion of pseudoresistance, identi-
fication of important contributing factors (such as diet and anti-
hypertensive drug compliance, and interfering substances) and 
diagnosis of underlying secondary causes of hypertension. The 
most common causes of pseudoresistance are white-coat 
hypertension and poor medicine adherence. Common factors 
contributing to development of resistance to antihypertensive 
treatment include high dietary salt intake, use of medications 
that can interfere with pharmacologic treatment, especially 
nonsteroidal anti-inflammatory agents, and lifestyle factors such 
as weight gain and lack of physical exercise. The likelihood of a 
secondary cause of hypertension is increased in patients with 
resistant hypertension. Renal parancymal disorders, renovascu-
lar diseases and primary hyperaldosteronism are the most com-
mon secondary causes of resistant hypertension, obstructive 
sleep apnea syndrome (OSAS) should be particularly evaluated 
in patients who are obese (1-3).
The purpose of this review is to discuss the diagnostic 
workup and management of resistant hypertension in patients 
with different clinical presentations.
Case 1
A 64-year-old man with a past history of essential hyperten-
sion that was once controlled with amlodipine monotherapy, pre-
sented with uncontrolled blood pressure despite taking multiple 
antihypertensive regimens (amlodipine 10 mg/day, carvedilol 25 
mg/day, lisinopril 10/ hydrochlorothiazide 12.5 mg/day) for 1 month. 
For the preceding 10 days he also began to have nausea, vomiting, 
and fatigue. His family history was remarkable for coronary artery 
disease and essential hypertension in his brother.
Findings on physical examination were as follows; blood 
pressure 190/110 mm Hg in both arms, pulse rate 96 beats/min 
and regular, and body mass index 27 kg/m2. He was dyspneic 
and orthopneic, bilateral inspiratory rales were heard in lungs 
on auscultation, and +2 bilateral pitting edema on both legs was 
noted. He gave up smoking 10 years ago. He has no history of 
alcohol or any agents interfering with blood pressure control.
Serum tests follows: hemoglobin: 10.3 g/L, blood urea nitrogen 
(BUN) 124 mg/dL, serum creatinine 14.4 mg/dL, sodium 136 mEq/L, 
potassium 6.0 mg/dL, calcium 7.9 mg/dL and phosphorus 13 mg/dL. 
The patient’s glomerular filtration rate was 4 ml/min according to 
MDRD formula, and urinary protein to creatinine ratio was 1.1. 
Arterial blood gas analysis showed a pH 7.24 and HCO3 18 mmol/L.
Electrocardiography revealed sinus rhythm with left ventric-
ular hypertrophy. Left ventricular hypertrophy,  mitral and tri-
cuspid regurgitation, and normal systolic function (EF >%60) 
were present at echocardiography. Grade II hypertensive reti-
nopathy was detected on fundus examination. Chest radiogra-
phy demonstrates bat wing alveolar edema with a central distri-
bution and sparing of the lung cortex.
The patient was hospitalized at intensive care unit because 
of high blood pressure complicated by target organ damage 
(hypertensive emergency; including acute kidney injury, and 
pulmonary edema). An intravenous antihypertensive regimen 
(nitroglycerin, furosemide) and hemodialysis therapy were initi-
ated. After 4 liter of fluid removal from the body by ultrafitration 
on two hemodialysis seasons, the patient’s blood pressure was 
decreased to about 150/100 mm Hg.
Renal ultrasonography revealed discrepancy between sizes 
of both kidneys with the left kidney being smaller. Digital sub-
traction angiography (DSA) was performed because of a high 
suspicion of renal artery stenosis. DSA showed complete occlu-
sion of the left renal artery and 95% stenotic right renal artery. 
After bilateral percutaneous transluminal angioplasty of the 
renal arteries (PTRA), stenotic right renal artery was revascular-
ized but it was not possible to vascularize left renal artery 
(Fig. 1A, B). Three days after the PTRA, renal function improved 
and blood pressure gradually decreased and thus antihyperten-
sive drug requirement was reduced. His blood pressure was 
controlled with amlodipine monotherapy. The patient was dis-
charged with a BUN 46 mg/dL, a creatinine 2.3 mg/dL, and a 
blood pressure of 130/80 mm Hg.
One year after the PTRA his mean blood pressure was below 
140/90 mm Hg with amlodipine 10 mg/day while serum BUN and 
creatinine levels were 32 mg/dL and creatinine 1.5 mg/dL 
respectively. In addition, right renal artery was patent on duplex 
ultrasonography.
Case 2
A 38-year-old woman presented with the complaints of weak-
ness, fatigue, and uncontrolled hypertension. The patient had had 
hypertension for 3 years, and had been taking 10 mg amlodipine and 
160 mg valsartan for control of blood pressure. Fifteen days ago val-
sartan dose was increased to 320 mg and 25 mg hydrochlorothiazide 
was added on her current antihypertensive medications because of 
uncontrolled blood pressure. She had no history of smoking, alcohol 
intake, or use of any medications known to increase blood pressure. 
She had lost 10 kg weight in last four years.
On physical examination, the patient’s blood pressure was 
160/85 mm Hg on right arm and 170/90 mm Hg on left arm, and her 
pulse rate was 82 beats/min, and body mass index was 35 kg/m2.
On laboratory examination serum potassium level was below 
the normal limit on two different samples (K: 3.1-3.3 mg/dL). 
Complete blood count, creatinine, sodium, calcium, liver func-
tions tests, fasting glucose and lipid profiles, thyroid function 
test, glomerular filtration rate, and urinary albumin excretion 
were within normal limits.
Electrocardiography showed normal sinus rhythm. Systolic 
function was normal on echocardiography and so was the fun-
dus examination.
Despite addition of metoplolol 100 mg/day and discontinua-
tion of hydrochlorothiazide because of hypokalemia, blood pres-
sure remained uncontrolled (office blood pressure was 160/100 
mm Hg and home blood pressure reading were 155-150/80-85 
mm Hg). As the patient had resistant hypertension combined 
with hypokalemia, she was evaluated for secondary hyperten-
sion including endocrine and renal causes. Renal ultrasonogra-
phy and duplex ultrasonography ruled out of renovascular and 
renal parancimal pathology. Plasma TSH, free metanephine, 
normetanephrine, fasting cortisol levels, and 24-hour urinary 
free cortisol level were within normal limits. Plasma aldosterone 
concentration (PAC) was 32 ng/dL (>15 ng/mL), plasma renin 
activity (PRA) was 0.8 ng/mL/h (<1 ng/ml/h), and PAC/PRA ratio 
was 40 (>20). Sodium loading test with measurement of 24 hour 
urine aldosterone excretion was done to confirm the diagnosis 
of primary hyperaldosteronism. The diagnosis of primary hyper-
aldoteronism was confirmed by a high 24 hour urine aldosterone 
level. No adrenal mass was found by computed tomography of 
adrenal glands. Because of a high possibility of bilateral idio-
pathic hyperplasia due to hyporeninemic hyperaldosteronism 
we started 100 mg spiranolactone therapy in addition to current 
optimal doses of 3 antihypertensive drugs (valsartan 320 mg/day, 
amlodipine 10 mg/day, and metoprolol 100 mg/day). One month 
after of spironolactone therapy blood pressure gradually 
decreased and metoprolol and amlodipine were withheld. Her 
blood pressure came under control (<140/90 mm Hg) with half 
dose valsartan 160 mg/day and spiranolactone 100 mg/day on 
the second month of spiranolactone therapy.
Case 3
A 62-year-old man with history of hypertension and dyslipid-
emia, was referred to our department for uncontrolled blood 
pressure. The patient had a history of HT that was once con-
Figure 1. Right proximal renal artery stenosis secondary to atherosclerosis. 
Before (A) and after (B) successful percutaneous angioplasty
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trolled with losartan 100 mg/day, amlodipine 10 mg/day, and 
carvedilol 12.5 mg/day since 10 days. Three days ago he had 
admitted to emergency room with chest pain related to high 
blood pressure (190/110 mm Hg). The cardiologist ruled out an 
acute coronary syndrome. Later the day his blood pressure 
decreased to 160/90 mm Hg by administration 25 mg sublingual 
captopril. The patient was discharged from emergency room 
with losartan 100/hydrochlorothiazide 12.5 mg/day.
He had not smoked cigarettes for 5 years. He usually takes 
non-steroidal anti-inflammatory drugs for headache.
On his physical examination blood pressure readings in right 
and left arms were 160/100 mm Hg and 150/90 mm Hg, respec-
tively: body mass index was 32.2 kg/m2. Other systemic exami-
nation was unremarkable.
Complete blood count, creatinine, electrolytes, liver function 
tests, glucose and thyroid function tests were all within normal limits. 
Lipid profile (total cholesterol: 250 mg/dL, low density lipoprotein 
cholesterol: 155 mg/dL, triglyceride: 200 mg/dL) and urinary albumin 
extraction (microalbuminuria 110 mg/day) were slightly elevated.
Electrocardiography revealed sinus rhythm. Echocardiography 
revealed left ventricular concentric hypertrophy, right atrial 
enlargement, and normal systolic function (EF >67%). Grade I 
hypertensive retinopathy was detected on fundus examination. No 
abdominal pathology was found on abdominal ultrasonography.
His blood pressure was still uncontrolled with optimal doses 
of 4 antihypertensive agents one of which was diuretic, and life 
still changes (low sodium consumption, regular exercise, and 
8 kg weight loss) in last 2 months. His office blood pressure was 
180/110 mm Hg and mean daytime blood pressure was 162/98 
mm Hg, and mean nocturnal blood pressure was 158/90 mm Hg, 
consistent with a non-dipper pattern. Doxazosin 4 mg/day was 
added to his previous drug regimen.
There were no signs of secondary causes of hypertension 
such as renovascular disease, primary aldosteronism, Cushing 
syndrome, pheochromocyctoma, and thyroid diseases.
A polysomnography (PSG) was performed to rule out OSAS 
owing to presence of morning asthenia with headache, dryness 
in the mouth and pharynx, and snoring. PSG revealed an apnea-
hypopnea index of 25/hour, which was consistent with moderate 
OSAS. Continuous positive airway pressure (CPAP) therapy was 
initiated with pressure of 8 cm H20 for 5 hours. One month later, 
blood pressure showed gradual decrease with concomitant 
improvement of symptoms. On ambulatory blood pressure moni-
toring (ABPM) new mean daytime blood pressure was 138/85 
mm Hg and mean nocturnal blood pressure was 122/74 mm Hg 
with a dipper pattern, and hence amlodipine, doxazosin and 
carvedilol were discontinued.
Blood pressure remained within normal limits (<140/90 mm Hg) 
at home and office controls with losartan 100 mg and 12.5 mg 
hydrochlorothiazide.
Discussion
Resistant hypertension is defined as blood pressure that 
remains above 140/90 mm Hg despite the concurrent use of 3 
antihypertensive agents of different classes at optimal doses. 
Ideally, 1 of the 3 agents should be diuretic agent. The etiology of 
resistant hypertension is multifactorial. The first step in assess-
ment of resistant hypertension is exclusion of pseudo-resis-
tance. Detailed questioning on adherence to prescribed medi-
cines and blood pressure measurement at home or ambulatory 
blood pressure monitoring exclude the most common causes of 
pseudo-resistance such as poor medication adherence and 
white coated hypertension.
Some medications often interfere with blood pressure con-
trol. Given their extensive use, non-steroidal anti-inflammatory 
drugs (NSAIDs) are the most common of such medications. 
These drugs worsen blood pressure control by resulting in 
sodium retention and vasoconstriction (1-3).
The main lifestyle factors contributing to drug-resistant 
hypertension are dietary sodium exposure and excess body 
weight. High dietary salt ingestion contributes importantly to the 
risk of developing hypertension but may also be a particularly 
important contributor to the development of resistant hyperten-
sion (4). Obesity is an independent risk factor for essential 
hypertension, and it also reduces benefit from pharmacologic 
treatment, thereby leading to an increased requirement of 
increased number of antihypertensive medications.
The prevalence of secondary hypertension is higher in 
patients with resistant hypertension than in the general hyper-
tensive population. Renovascular disease is an important cause 
of secondary hypertension. Atherosclerotic renal artery stenosis 
(ARAS) is associated with two common clinical syndromes: reno-
vascular hypertension and ischemic nephropathy, which often 
coexist. The ensuing renovascular disease constitutes the fast-
est-growing etiology of end-stage renal disease. Certain clues in 
the patient’s medical history and laboratory parameters may help 
identify the secondary hypertension related with renovascular 
disease (RVD). Early or late onset of hypertension, acceleration 
of treated hypertension, progressive deterioration of renal func-
tion in treatments with angiotensin converting enzyme inhibitors 
(ACEI), repeated flush pulmonary edema, known coronary artery 
disease, evidence of vascular disease in the neck (bruits) or the 
legs (claudication), and renal asymmetry in hypertensive patients 
represent strong clinical indications for evaluation (5).
Diagnostic work-up for hemodynamically significant renal 
artery stenosis should be restricted to patients suspected to be 
at moderate or high risk RVD. Patients at high risk for RVD may 
be directly referred for renal artery angiography, the golden 
standard diagnostic procedure.
A renal artery stenosis with narrowing of > 60% of the lumen, 
is considered hemodynamically significant, and may be suitable 
for treatment with angioplasty or angioplasty plus stent place-
ment. Objectives for endovascular or surgical therapy of renal 
artery stenosis include optimization of blood pressure control, 
preservation of renal function, and prevention of complications 
such as recurrent flash pulmonary edema (6). In our first case 
report, suspicion for the presence of RVD was very strong 
because of rapidly impaired renal functions after starting treat-
ment with ACEI, presence of renal asymmetry, and previously 
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smoking habits concurrently with uncontrolled blood pressure 
with multiple antihypertensive agents. After successful balloon 
angioplasty plus stent replacement against right renal artery 
stenosis, antihypertensive drug requirement gradually 
decreased and renal functions were improved. The blood pres-
sure is still under control with amlodipine monotherapy.
The clinical syndrome of hypertension combined with hypoka-
lemia may be related to low renin state, such as primary hyperal-
dosteronism, adrenal enzyme defects, certain familial syndromes, 
and licorice ingestion. Primary aldosteronism is now the most 
common secondary cause of resistant hypertension. The preva-
lence of hyperaldosteronism in the hypertensive population is 
5-12% (7-9), bilateral adrenal hyperplasia and aldosterone-pro-
ducing adenoma are the two main causes. The diagnosis is based 
on the aldosterone/renin ratio as a screening test, subsequent 
confirmatory tests, and CT/MR imaging studies. If the aldosterone/
renin ratio is increased, and plasma aldosterone concentration is 
appropriately elevated, 24 hour urine aldosteron measurement 
after sodium loading should be performed. Once the diagnosis of 
primary hyperaldosteronism is confirmed, CT imaging of adrenal 
glands should be performed to determine the subtype of primary 
hyperaldosteronism. Management of primary hyperaldosteronism 
includes surgical resection for unilateral adrenal disease and 
mineralocorticoid receptor antagonists for bilateral disease (10, 
11). In our second case report, the patient began to have a normal 
blood pressure and serum potassium level after commencing 
spironolactone treatment. Drug resistant hypertension was 
improved due to blockage of aldosterone effects.
OSAS is a sleep disorder that was characterized by at least 
10 apnea-hypopnea events every per hour during sleep (12, 13). 
Although OSAS is not a classical form of “secondary hyperten-
sion, it is commonly present in the drug-resistant hypertension, 
the clinical picture of which includes four main symptoms: day-
time sleepiness, frequent nocturnal micro-arousals, morning 
asthenia with or without headache, and severe snoring (14). The 
use of CPAP at night time in patients with OSAS prevents sym-
pathetic overactivity, thus improving blood pressure control (15, 
16). Our third case highlights a possible association between 
OSAS and resistant hypertension, with a good blood pressure 
lowering effect after with CPAP therapy. Thus, it is reasonable to 
include OSAS in different diagnosis of resistant hypertension.
Conclusion
Resistant hypertension is a significant clinical problem com-
monly encountered by clinicians. Evaluation of a patient with 
resistant hypertension requires recognize of factors that con-
tribute to pseudo-resistance to treatment, and identification of 
important contributing factors such as high salt intake, heavy 
alcohol consumption, and use of interfering medications. 
Secondary causes of hypertension are common in patients with 
resistant hypertension and should be addressed in the diagnos-
tic workup. Treatment should include appropriate lifestyle 
changes and prescription of effective antihypertensive drugs.
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